GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (NAS:ACAD) » Definitions » Book Value per Share

ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Book Value per Share : $2.62 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Book Value per Share?

ACADIA Pharmaceuticals's book value per share for the quarter that ended in Dec. 2023 was $2.62.

During the past 12 months, ACADIA Pharmaceuticals's average Book Value Per Share Growth Rate was 6.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -12.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -8.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ACADIA Pharmaceuticals was 91.30% per year. The lowest was -48.00% per year. And the median was 7.60% per year.

ACADIA Pharmaceuticals's current price is $17.48. Its book value per share for the quarter that ended in Dec. 2023 was $2.62. Hence, today's PB Ratio of ACADIA Pharmaceuticals is 6.67.

During the past 13 years, the highest P/B Ratio of ACADIA Pharmaceuticals was 17.81. The lowest was 4.54. And the median was 9.05.

Good Sign:

ACADIA Pharmaceuticals Inc stock PB Ratio (=6.37) is close to 1-year low of 6.37


ACADIA Pharmaceuticals Book Value per Share Historical Data

The historical data trend for ACADIA Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Book Value per Share Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.50 3.93 3.36 2.47 2.62

ACADIA Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 2.31 2.42 2.21 2.62

Competitive Comparison of ACADIA Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, ACADIA Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's PB Ratio falls into.



ACADIA Pharmaceuticals Book Value per Share Calculation

ACADIA Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(431.8-0.0)/164.7
=2.62

ACADIA Pharmaceuticals's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(431.8-0.0)/164.7
=2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


ACADIA Pharmaceuticals  (NAS:ACAD) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


ACADIA Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Executives
Austin D. Kim officer: EVP & General Counsel C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Brendan Teehan officer: EVP, COO, Head of Commercial C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Stephen Davis director, officer: PRESIDENT AND CEO ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James Kihara officer: Principal Accounting Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark C. Schneyer officer: Chief Financial Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Douglas J Williamson officer: Executive VP, Research & Dev AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Srdjan R. Stankovic officer: EVP C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Adora Ndu director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Elena Ridloff officer: EVP and CFO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Michael J. Yang officer: EVP AND CCO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Eric Alejandro Miller officer: Controller & PAO C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130